IMR Press / EJGO / Volume 36 / Issue 6 / DOI: 10.12892/ejgo2709.2015

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Open Access Original Research
Surgical Stage I high-grade ovarian cancer: is adjuvant chemotherapy warranted?
Show Less
1 Departments of Obstetrics and Gynecology, Division of Gynecologic Oncology
2 Pathology, University of Toronto, Sunnybrook Hospital and Health Sciences Center, Toronto, Ontario (Canada)
Eur. J. Gynaecol. Oncol. 2015, 36(6), 633–636;
Published: 10 December 2015

Objective: To review the results of patients with high-grade Stage I ovarian cancer managed without adjuvant treatment. Materials and Methods: A retrospective chart review identified patients with newly diagnosed Stage I high-grade ovarian cancer, who underwent comprehensive surgical staging. Results: Thirty-three patients with FIGO surgical Stage I high-grade ovarian cancer were identified. After a median follow-up of 40 months, nine patients (27%) recurred. The median time to recurrence was 19 months. Of the nine patients with recurrences, four (44%) are alive with disease, three (33%) patients have no evidence of disease, and two have died of disease (22%). The two- and five-year overall survival is 100% and 90%, respectively. Conclusions: It would appear the recurrence rates of Stage I high risk epithelial ovarian cancer completely staged, without adjuvant treatment are comparable to those of treatment arms reported in the literature. A proportion of these patients can be salvaged at recurrence, yielding a high overall survival.
Ovarian cancer
Surgical staging
Adjuvant chemotherapy
High grade
Early stage
Back to top